{"id":12471,"date":"2025-05-14T09:26:42","date_gmt":"2025-05-14T13:26:42","guid":{"rendered":"https:\/\/www.rigicon.com\/glossary-term\/alpha-blockers\/"},"modified":"2026-03-22T06:33:36","modified_gmt":"2026-03-22T10:33:36","slug":"bloqueadores-alfa-pt-br","status":"publish","type":"glossary-term","link":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","title":{"rendered":"Bloqueadores Alfa"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":0,"template":"","glossary-category":[114],"glossary-product":[104,105],"class_list":["post-12471","glossary-term","type-glossary-term","status-publish","hentry","glossary-category-urological-agents","glossary-product-infla10-pulse-ipp-series","glossary-product-rigi10-malleable-penile-prosthesis"],"acf":{"gt-definition":"<p>Os alfa-bloqueadores, tamb\u00e9m conhecidos como antagonistas alfa-adren\u00e9rgicos, s\u00e3o uma classe de medicamentos farmac\u00eauticos que atuam bloqueando os receptores alfa-adren\u00e9rgicos (receptores alfa) no sistema nervoso simp\u00e1tico. Essa a\u00e7\u00e3o evita que catecolaminas como a norepinefrina e a epinefrina se liguem a esses receptores, levando a diversos efeitos fisiol\u00f3gicos. Seu objetivo principal \u00e9 relaxar certos m\u00fasculos e ajudar os pequenos vasos sangu\u00edneos a permanecerem abertos. Ao bloquear a a\u00e7\u00e3o dos nervos no sistema nervoso simp\u00e1tico, eles podem melhorar o fluxo sangu\u00edneo e reduzir a press\u00e3o arterial. Eles tamb\u00e9m s\u00e3o usados \u200b\u200bpara relaxar o t\u00f4nus \u200b\u200bmuscular da pr\u00f3stata e do colo da bexiga, melhorando assim o fluxo urin\u00e1rio em condi\u00e7\u00f5es como a hiperplasia prost\u00e1tica benigna (HPB). Os alfa-bloqueadores s\u00e3o amplamente categorizados em alfa-bloqueadores n\u00e3o seletivos (que bloqueiam os receptores alfa-1 e alfa-2) e alfa-bloqueadores seletivos (que t\u00eam como alvo principal os receptores alfa-1 ou alfa-2). Os bloqueadores alfa-1 seletivos s\u00e3o comumente usados \u200b\u200bpara hipertens\u00e3o e HBP, enquanto os alfa-bloqueadores n\u00e3o seletivos t\u00eam usos mais especializados, como no tratamento do feocromocitoma. O mecanismo espec\u00edfico envolve a modula\u00e7\u00e3o do t\u00f4nus \u200b\u200b\u200b\u200bvascular e a libera\u00e7\u00e3o de noradrenalina, levando \u00e0 vasodilata\u00e7\u00e3o e relaxamento do m\u00fasculo liso, dependendo do subtipo e localiza\u00e7\u00e3o do receptor.\u207d\u00b9\u207e\u207d\u00b9\u2075\u207e<\/p>\n<p>Os bloqueadores alfa (alfa-bloqueadores) s\u00e3o medicamentos que relaxam a musculatura lisa da pr\u00f3stata, colo vesical e ureter ao bloquear os receptores alfa-adren\u00e9rgicos. Na urologia, s\u00e3o amplamente utilizados no tratamento dos sintomas do trato urin\u00e1rio inferior (STUI) associados \u00e0 hiperplasia prost\u00e1tica benigna (HPB) e como terapia expulsiva de c\u00e1lculos ureterais distais.<\/p>","gt-synonyms":"Antagonistas alfa-adren\u00e9rgicos, antagonistas dos receptores alfa-adren\u00e9rgicos, bloqueadores alfa, agentes bloqueadores alfa-adren\u00e9rgicos","gt-citation":"[1] Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007 Nov;92(11):4069-79. doi: 10.1210\/jc.2007-1720. Epub 2007 Sep 11. PMID: 17848402.\n\n[2] Ramachandran R, Rewari V. Perioperative management of pheochromocytoma. Indian J Urol. 2017 Jan-Mar;33(1):19-25. doi: 10.4103\/0970-1591.195716. PMID: 28197011; PMCID: PMC5264186.\n\n[3] Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Wipfler MG, Lange RA. \u03b2-Blockers, Cocaine, and the Unopposed \u03b1-Stimulation Phenomenon. J Cardiovasc Pharmacol Ther. 2017 May;22(3):239-249. doi: 10.1177\/1074248416680577. Epub 2016 Nov 29. PMID: 27899671.\n\n[4] Page RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J., American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69. doi: 10.1161\/CIR.0000000000000426. Erratum in: Circulation. 2016 Sep 20;134(12):e261. Erratum in: Circulation. 2017 Jan 31;135(5):e20. PMID: 27400984.\n\n[5] Thadchanamoorthy V, Dayaratna T. Phentolamine. StatPearls Publishing; 2024 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564363\/\n\n[6] McMahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust. 2019 Sep;211(6) :280-285. doi: 10.5694\/mja2.50329. Epub 2019 Aug 18. PMID: 31422605.\n\n[7] Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012 May;109(9):1397-401. doi: 10.1111\/j.1464-410X.2011.10530.x. Epub 2011 Sep 26. PMID: 21951404.\n\n[8] Duncan C, Omran M, Teh J, Davis N, Kuan M, DCRC study group. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019 Jun;37(6):1007-1014. doi: 10.1007\/s00345-019-02704-7. Epub 2019 Mar 11. PMID: 30859279.\n\n[9] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001\/jama.289.19.2560. Erratum in: JAMA. 2003 Jul 9;290(2):197. PMID: 12748199.\n\n[10] AUA Guideline on Management of Benign Prostatic Hyperplasia (BPH). American Urological Association. Updated 2023. Available from: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/benign-prostatic-hyperplasia-(bph -guideline\n\n[11] Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998 Feb;159(2):433-6. doi: 10.1016\/s0022-5347(01)63942-x. PMID: 9649257.\n\n[12] Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther. 2001 Sep;91(3):215-43. doi: 10.1016\/s0163-7258(01)00156-5. PMID: 11744068.\n\n[13] Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. 2006 Oct-Dec;14(4):289-99. doi: 10.1080\/15438620600987106. PMID: 17214405.\n\n[14] Morales A. Yohimbine in erectile dysfunction: the facts. Int J Impot Res. 2000 Mar;12 Suppl 1:S70-4. doi: 10.1038\/sj.ijir.3900501. PMID: 10743698.\n\n[15] Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology. 12th ed. McGraw-Hill Medical; 2012.\n\n[16] Hoffman BB. Adrenoceptor-Blocking Drugs. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011. p. 279-302.\n\n[17] Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. PMID: 18231614; PMCID: PMC2213889.\n\n[18] Rovner ES, Guralnick ML, Issa MM, Bresette JF, Foote JE, Karram MM, Nitti VW, Raz S, Sussman DO, Walter K, Zinner NR., Tamsulosin LUTS Study Group. Tamsulosin for the treatment of lower urinary tract symptoms in women: a randomized, double-blind, placebo-controlled trial. J Urol. 2005 Mar;173(3):843-7. doi: 10.1097\/01.ju.0000152971.02985.7b. PMID: 15711050.\n\n[19] Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol. 2009 Sep;56(3):455-71. doi: 10.1016\/j.eururo.2009.06.012. Epub 2009 Jun 17. PMID: 19556043.\n\n[20] Hollingsworth JM, Canales BK, Rogers MA, Sukumar S, Yan P, Kuntz GM, Dahm P, Hollenbeck BK. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016 Oct 26;355:i5424. doi: 10.1136\/bmj.i5424. PMID: 27784695; PMCID: PMC5082933.\n\n[21] Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2018 Apr 11;4(4):CD008509. doi: 10.1002\/14651858.CD008509.pub3. PMID: 29637541; PMCID: PMC6494465.\n\n[22] Pickard R, Starr K, MacLennan G, Lam T, Thomas R, Burr J, Norrie J, McPherson G, McDonald A, Anson K, N'Dow J, Burgess N, Clark T, Kilonzo M, Gillies K, Boachie C, Erasmus P, McClinton S, Goodman C., SUSPEND Study Group. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Jul 25;386(9991):341-9. doi: 10.1016\/S0140-6736(15)60933-3. Epub 2015 May 19. PMID: 26003623.\n\n[23] Ye Z, Zeng G, Yang H, Tang K, Zhang X, Li H, Li W, Wu S, Chen L, Chen X, Liu X, Deng Y, Pan T, Xing C, Wang S, Cheng Y, Gao X. Efficacy and Safety of Silodosin in the Medical Expulsive Therapy for Distal Ureteral Stones: A Systematic Review and Meta-Analysis. Urol Int. 2018;100(1):17-29. doi: 10.1159\/000480310. Epub 2017 Oct 18. PMID: 29041010.\n\n[24] Sharma G, Laddha A, Athyal UR, Singh V. Silodosin versus tamsulosin for medical expulsion therapy of ureteral stones: A systematic review and meta-analysis. Arab J Urol. 2019 Mar 21;17(2):130-139. doi: 10.1080\/2090598X.2019.1586232. PMID: 31285889; PMCID: PMC6584089.\n\n[25] Cui Y, Chen J, Yang S, Zong H, Zhang Y. Silodosin versus tamsulosin for the management of lower ureteral stones: a meta-analysis. Urolithiasis. 2015 Feb;43(1):61-7. doi: 10.1007\/s00240-014-0727-0. Epub 2014 Nov 20. PMID: 25410298.\n\n[26] Corona G, Rastrelli G, Burri A, Jannini EA, Maggi M. The safety and efficacy of alpha-blockers for the treatment of premature ejaculation: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017 Mar;16(3):301-309. doi: 10.1080\/14740338.2017.1283399. Epub 2017 Jan 25. PMID: 28097895.\n\n[27] Nickel JC, M\u00e9ndez-Probst CE, Whelan TF, Paterson RF, Razvi H. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. 2010 Oct;4(5):310-6. doi: 10.5489\/cuaj.10124. PMID: 20941312; PMCID: PMC2950766.\n","gt-clinical-context":"<p>Os alfa-bloqueadores s\u00e3o utilizados em v\u00e1rios cen\u00e1rios cl\u00ednicos, principalmente para o tratamento da hiperplasia prost\u00e1tica benigna (HPB) e da hipertens\u00e3o.\u207d\u2079\u207e\u207d\u00b9\u2070\u207e\u207d\u00b9\u2077\u207e Na HBP, bloqueadores alfa-1 seletivos como tansulosina, alfuzosina e silodosina s\u00e3o considerados agentes de primeira linha. Eles atuam relaxando o m\u00fasculo liso da pr\u00f3stata e do colo da bexiga, o que alivia os sintomas do trato urin\u00e1rio inferior (STUI), como dificuldade para urinar, jato fraco e noct\u00faria. O al\u00edvio sintom\u00e1tico \u00e9 frequentemente observado alguns dias ap\u00f3s o in\u00edcio da terapia.\u207d\u00b9\u2070\u207e A sele\u00e7\u00e3o de pacientes para HBP geralmente envolve homens com STUI moderados a graves que n\u00e3o t\u00eam contra-indica\u00e7\u00f5es para a terapia com alfa-bloqueadores. Os resultados esperados incluem melhora nas taxas de fluxo urin\u00e1rio e redu\u00e7\u00e3o nos escores de sintomas.<\/p>\n<p>Para hipertens\u00e3o, alfa-bloqueadores como doxazosina e prazosina s\u00e3o geralmente considerados agentes de segunda linha devido a potenciais efeitos adversos, como hipotens\u00e3o ortost\u00e1tica.\u207d\u2079\u207e Eles s\u00e3o usados quando outros anti-hipertensivos s\u00e3o insuficientes ou contraindicados. Esses medicamentos reduzem a press\u00e3o arterial, causando vasodilata\u00e7\u00e3o dos vasos sangu\u00edneos perif\u00e9ricos. A sele\u00e7\u00e3o dos pacientes envolve uma considera\u00e7\u00e3o cuidadosa dos fatores de risco cardiovascular e do potencial para sintomas ortost\u00e1ticos. Os resultados esperados s\u00e3o uma redu\u00e7\u00e3o na press\u00e3o arterial sist\u00eamica.<\/p>\n<p>Os alfabloqueadores n\u00e3o seletivos, fenoxibenzamina e fentolamina, s\u00e3o aprovados pela FDA para o tratamento do feocromocitoma, um tumor raro da medula adrenal que secreta catecolaminas em excesso. Eles s\u00e3o usados \u200b\u200bno pr\u00e9-operat\u00f3rio e no intraoperat\u00f3rio para controlar crises hipertensivas.\u207d\u00b9\u207e\u207d\u00b2\u207e A fentolamina tamb\u00e9m tem usos off-label, incluindo o tratamento de complica\u00e7\u00f5es cardiovasculares induzidas por coca\u00edna e como um componente da terapia de inje\u00e7\u00e3o intracavernosa (Trimix) para homens er\u00e9teis disfun\u00e7\u00e3o.\u207d\u00b3\u207e\u207d\u2074\u207e\u207d\u2075\u207e\u207d\u2076\u207e\u207d\u2077\u207e\u207d\u2078\u207e<\/p>\n<p>Os alfabloqueadores, particularmente os antagonistas alfa-1 seletivos, como a silodosina e a tansulosina, tamb\u00e9m s\u00e3o empregados como terapia m\u00e9dica expulsiva (TEM) de primeira linha para c\u00e1lculos ureterais (c\u00e1lculos renais), especialmente aqueles localizados no ureter distal. Eles relaxam a musculatura lisa ureteral, facilitando a passagem espont\u00e2nea de pedras.\u207d\u00b9\u2079\u207e\u207d\u00b2\u2070\u207e\u207d\u00b2\u00b9\u207e\u207d \u00b2\u00b2\u207e\u207d\u00b2\u00b3\u207e\u207d\u00b2\u2074\u207e\u207d\u00b2\u2075\u207e A terapia normalmente \u00e9 continuada por at\u00e9 tr\u00eas semanas. Os alfa-bloqueadores tamb\u00e9m demonstraram alguma efic\u00e1cia no tratamento da ejacula\u00e7\u00e3o precoce, embora possam afetar o volume do s\u00eamen.\u207d\u00b2\u2076\u207e Al\u00e9m disso, a terapia com alfa-bloqueadores pode ser considerada para pacientes do sexo feminino com reten\u00e7\u00e3o urin\u00e1ria ou outros STUI.\u207d\u00b9\u2078\u207e<\/p>\n<p>Os procedimentos cir\u00fargicos n\u00e3o est\u00e3o diretamente associados \u00e0 administra\u00e7\u00e3o de alfabloqueadores em si, mas esses medicamentos costumam fazer parte da estrat\u00e9gia de tratamento m\u00e9dico para condi\u00e7\u00f5es que podem eventualmente exigir cirurgia (por exemplo, HPB progredindo para exigir ressec\u00e7\u00e3o transuretral da pr\u00f3stata se a terapia m\u00e9dica falhar ou for insuficiente). No contexto do feocromocitoma, o bloqueio alfa \u00e9 uma parte cr\u00edtica da prepara\u00e7\u00e3o perioperat\u00f3ria para a remo\u00e7\u00e3o cir\u00fargica do tumor.\u207d\u00b9\u207e\u207d\u00b2\u207e<\/p>\n<p>As diretrizes da EAU recomendam alfa-bloqueadores (tansulosina, alfuzosina, silodosina) como tratamento de primeira linha para STUI moderados a graves. O efeito \u00e9 r\u00e1pido, com melhora em poucos dias. Na terapia expulsiva de c\u00e1lculos, a tansulosina facilita a elimina\u00e7\u00e3o espont\u00e2nea de c\u00e1lculos ureterais distais < 10 mm. Os principais efeitos colaterais incluem hipotens\u00e3o ortost\u00e1tica e ejacula\u00e7\u00e3o retr\u00f3grada.<\/p>","gt-related-evidence":null,"gt-featured":false,"gt-ai-referenced":false,"gt-view-count":166},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.7 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon<\/title>\n<meta name=\"description\" content=\"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bloqueadores Alfa: Usos, Mecanismo, and Tratamento for BPH &amp; HTN\" \/>\n<meta property=\"og:description\" content=\"Alfa-bloqueadores: Aprenda sobre esses medicamentos usados \u200b\u200bpara hipertens\u00e3o (HTN) e HBP, seu mecanismo e aplica\u00e7\u00f5es cl\u00ednicas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/\" \/>\n<meta property=\"og:site_name\" content=\"Rigicon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/rigiconurology\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-22T10:33:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rigicon.com\/wp-content\/uploads\/2025\/05\/header-d.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"718\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Bloqueadores Alfa: Usos, Mecanismo, and Tratamento for BPH &amp; HTN\" \/>\n<meta name=\"twitter:description\" content=\"Alfa-bloqueadores: Aprenda sobre esses medicamentos usados \u200b\u200bpara hipertens\u00e3o (HTN) e HBP, seu mecanismo e aplica\u00e7\u00f5es cl\u00ednicas.\" \/>\n<meta name=\"twitter:site\" content=\"@rigiconurology\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/\",\"name\":\"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#website\"},\"datePublished\":\"2025-05-14T13:26:42+00:00\",\"dateModified\":\"2026-03-22T10:33:36+00:00\",\"description\":\"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glossary Terms\",\"item\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/urology-glossary\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bloqueadores Alfa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#website\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\",\"name\":\"Rigicon\",\"description\":\"Innovative Urological Solutions\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#organization\"},\"alternateName\":\"Innovative Urological Solutions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#organization\",\"name\":\"Rigicon, Inc.\",\"alternateName\":\"Innovative Urological Solutions\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"width\":512,\"height\":512,\"caption\":\"Rigicon, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/x.com\\\/rigiconurology\",\"https:\\\/\\\/www.instagram.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@Rigicon\\\/podcasts\",\"https:\\\/\\\/www.youtube.com\\\/Rigicon\",\"https:\\\/\\\/www.threads.net\\\/@rigiconurology\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/rigicon\\\/\"],\"description\":\"Rigicon is a global provider of innovative, diverse, and complete portfolio of prosthetic urology options.\",\"email\":\"operations@rigicon.com\",\"telephone\":\"+1 (888) 202-9790\",\"legalName\":\"Rigicon, Inc.\",\"vatID\":\"81-3545645\",\"taxID\":\"81-3545645\",\"duns\":\"045247683\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon","description":"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","og_locale":"pt_BR","og_type":"article","og_title":"Bloqueadores Alfa: Usos, Mecanismo, and Tratamento for BPH & HTN","og_description":"Alfa-bloqueadores: Aprenda sobre esses medicamentos usados \u200b\u200bpara hipertens\u00e3o (HTN) e HBP, seu mecanismo e aplica\u00e7\u00f5es cl\u00ednicas.","og_url":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","og_site_name":"Rigicon","article_publisher":"https:\/\/www.facebook.com\/rigiconurology\/","article_modified_time":"2026-03-22T10:33:36+00:00","og_image":[{"width":1440,"height":718,"url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2025\/05\/header-d.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"Bloqueadores Alfa: Usos, Mecanismo, and Tratamento for BPH & HTN","twitter_description":"Alfa-bloqueadores: Aprenda sobre esses medicamentos usados \u200b\u200bpara hipertens\u00e3o (HTN) e HBP, seu mecanismo e aplica\u00e7\u00f5es cl\u00ednicas.","twitter_site":"@rigiconurology","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","url":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","name":"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon","isPartOf":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#website"},"datePublished":"2025-05-14T13:26:42+00:00","dateModified":"2026-03-22T10:33:36+00:00","description":"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.","breadcrumb":{"@id":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/www.rigicon.com\/pt-br\/"},{"@type":"ListItem","position":2,"name":"Glossary Terms","item":"https:\/\/www.rigicon.com\/pt-br\/urology-glossary\/"},{"@type":"ListItem","position":3,"name":"Bloqueadores Alfa"}]},{"@type":"WebSite","@id":"https:\/\/www.rigicon.com\/pt-br\/#website","url":"https:\/\/www.rigicon.com\/pt-br\/","name":"Rigicon","description":"Innovative Urological Solutions","publisher":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#organization"},"alternateName":"Innovative Urological Solutions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rigicon.com\/pt-br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.rigicon.com\/pt-br\/#organization","name":"Rigicon, Inc.","alternateName":"Innovative Urological Solutions","url":"https:\/\/www.rigicon.com\/pt-br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.rigicon.com\/pt-br\/#\/schema\/logo\/image\/","url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","contentUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","width":512,"height":512,"caption":"Rigicon, Inc."},"image":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/rigiconurology\/","https:\/\/x.com\/rigiconurology","https:\/\/www.instagram.com\/rigiconurology\/","https:\/\/www.youtube.com\/@Rigicon\/podcasts","https:\/\/www.youtube.com\/Rigicon","https:\/\/www.threads.net\/@rigiconurology","https:\/\/www.linkedin.com\/company\/rigicon\/"],"description":"Rigicon is a global provider of innovative, diverse, and complete portfolio of prosthetic urology options.","email":"operations@rigicon.com","telephone":"+1 (888) 202-9790","legalName":"Rigicon, Inc.","vatID":"81-3545645","taxID":"81-3545645","duns":"045247683"}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-term\/12471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-term"}],"about":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/types\/glossary-term"}],"wp:attachment":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/media?parent=12471"}],"wp:term":[{"taxonomy":"glossary-category","embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-category?post=12471"},{"taxonomy":"glossary-product","embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-product?post=12471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}